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Computer-aided detection/diagnosis (CAD) is increasingly used for decision support by clinicians for
detection and interpretation of diseases. However, there are no quality assurance (QA) requirements
for CAD in clinical use at present. QA of CAD is important so that end users can be made aware
of changes in CAD performance both due to intentional or unintentional causes. In addition, end-
user training is critical to prevent improper use of CAD, which could potentially result in lower
overall clinical performance. Research on QA of CAD and user training are limited to date. The
purpose of this paper is to bring attention to these issues, inform the readers of the opinions of the
members of the American Association of Physicists in Medicine (AAPM) CAD subcommittee, and
thus stimulate further discussion in the CAD community on these topics. The recommendations in
this paper are intended to be work items for AAPM task groups that will be formed to address QA
and user training issues on CAD in the future. The work items may serve as a framework for the
discussion and eventual design of detailed QA and training procedures for physicists and users of
CAD. Some of the recommendations are considered by the subcommittee to be reasonably easy and
practical and can be implemented immediately by the end users; others are considered to be “best
practice” approaches, which may require significant effort, additional tools, and proper training to
implement. The eventual standardization of the requirements of QA procedures for CAD will have to
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be determined through consensus from members of the CAD community, and user training may
require support of professional societies. It is expected that high-quality CAD and proper use of CAD
could allow these systems to achieve their true potential, thus benefiting both the patients and the
clinicians, and may bring about more widespread clinical use of CAD for many other diseases and
applications. It is hoped that the awareness of the need for appropriate CAD QA and user training will
stimulate new ideas and approaches for implementing such procedures efficiently and effectively as
well as funding opportunities to fulfill such critical efforts. © 2013 American Association of Physicists
in Medicine. [http://dx.doi.org/10.1118/1.4807642]
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I. INTRODUCTION
For over a decade, computer-aided detection/diagnosis (CAD)
has become a part of routine clinical practice. CAD is increas-
ingly used for decision support by healthcare professionals
for detection and interpretation of diseases occurring in vari-
ous organs of the body.1 Initial clinical applications of CAD
included detection of cancer in breast, lung, and colon exam-
inations. CAD is also rapidly expanding to provide additional
functionalities such as estimates of the likelihood of a lesion
being malignant or the risk of developing a disease, quan-
titative measurement tools (e.g., automated segmentation of
lesions, size measurement, dynamic flow information), treat-
ment planning, treatment response monitoring, and patient
outcome prediction by image-based biomarkers alone or in
combination with other clinical information. The acceptance
of CAD by clinicians would lead to further improvement in
the current CAD systems and opportunities for research and
development of new applications.
CAD products can be accepted in clinical use only if they
can provide clinical benefit that outweighs the potential asso-
ciated risks. There are many aspects of CAD that are impor-
tant to meet this goal. All along the lifecycle of a CAD system
(i.e., initiation, concept development, planning, requirements,
design, development, verification and validation, implemen-
tation, operations, and maintenance), a certain degree of qual-
ity assessment is already performed mainly by device manu-
facturers and by interactions between manufacturers and end
users (i.e., healthcare professionals), academia, and govern-
ment entities. However, there is only limited training offered
to the end users and limited quality assurance (QA) testing
performed on the system. For example, no requirements or
procedures have been developed to assure and analyze the
quality of CAD and the use of CAD over time at clinical sites.
Therefore, the end users may not be alerted to any unexpected
changes in CAD performance and do not have the ability to
easily identify any potential issue that may arise.
There are two crucial aspects to consider with CAD:
 Ensure that CAD products function correctly when
installed at a clinical site and continue to function cor-
rectly during clinical use. While these computer-based
techniques are typically reliable, consistent, and accu-
rate, inadvertent corruption of these systems or signifi-
cant changes in a site’s imaging systems or differences
in patient population may result in a decrease in CAD
performance that could substantially change the orig-
inally established risk-benefit profile. Therefore, it is
important that QA procedures for CAD products be de-
veloped, implemented, advocated, and potentially re-
quired/enforced at clinical sites so that the end users
or QA personnel can routinely check CAD performance
and identify any significant changes in performance.
 Monitor how these CAD products are being used by
end users, particularly clinicians. Even though CAD
products are recommended to be used in a certain man-
ner (e.g., second read), the end users may opt for a dif-
ferent use that may be less effective or inappropriate and
may change the risk-benefit profile. Studies have shown
that training end users on the appropriate use of CAD is
an important factor that may limit the potential change
of risk-benefit profile of the system.2
In late 2007, the American Association of Physicists
in Medicine (AAPM) officially created a Computer Aided
Detection in Diagnostic Imaging subcommittee (CADSC)
“to keep the membership apprised of new developments in
computer-assisted detection and diagnosis in medical imag-
ing and to develop techniques, practices, and standards that
address issues in the field as they arise.” This effort preceded
the Radiological Devices Advisory Panel meeting in March
of 2008, convened by the U.S. Food and Drug Administra-
tion (FDA), which discussed the current experience with and
concerns about CAD devices and sought regulatory and sci-
entific recommendations from outside experts on CAD. The
AAPM CADSC has a membership and participants of diverse
backgrounds and experiences (radiologists, CAD manufactur-
ers, academic researchers, and government entities) (see the
Appendix). The CADSC has conducted extensive discussions
and formed subgroups to address issues related to CAD in
four major areas:
 Methodologies for evaluation of standalone CAD sys-
tem performance,
 Methodologies for evaluation of effects of CAD on
users—standardization of CAD evaluation technologies,
 Develop QA procedure recommendations for CAD sys-
tems implemented in clinical use,
 Develop training and QA procedure recommendations
for using CAD system.
The purpose of this paper is to review the current status
of the work done on the last two topics (i.e., CAD QA and
training practices), share the rationale for establishing formal
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QA and training procedures for CAD use in clinical sites, pro-
pose preliminary recommendations on CAD QA and training
procedures, and discuss the off-label use issue, as well as the
next steps moving forward to the clinical arena (i.e., poten-
tial mechanisms for an effective implementation of a CAD
QA program at clinical sites and research and funding op-
portunities). The proposed recommendations are the opinions
of the members of the AAPM CADSC, and intended to be
work items for AAPM task groups that will be formed to ad-
dress QA and user training issues on CAD in the future. The
work items may serve as a framework for the discussion and
eventual design of detailed QA and training procedures for
physicists and users of CAD. It is hoped that, by recogniz-
ing the need for appropriate CAD QA and user training to
ensure the effectiveness of CAD in clinical practice, the com-
munity will begin to work on developing and implementing
some of the procedures. The potential benefits of improved
quality and scientific rigor of CAD in clinical use may even-
tually outweigh the costs associated with QA requirements
and regulations.
II. RATIONALE AND RECOMMENDED
PROCEDURES FOR QA OF CAD
AT CLINICAL SITES
The goal of this section is to recommend a set of general
guidelines on CAD QA procedures. Note that the proposed set
of guidelines as contained in this paper has been established
through discussions among a number of experts in CAD who
worked through a series of questions (see Sec. II.A) and re-
viewed various scenarios in order to understand why a CAD
QA program may be needed, what CAD QA would require in
terms of effort and cost, and how CAD QA procedures could
be performed. Sections II.B and II.C present detailed proce-
dures required to assure that a CAD system functions and per-
forms according to vendor’s specifications and to assure con-
sistency of its performance over time, respectively. Note that
some of the recommendations are considered by the subcom-
mittee to be reasonably easy and practical and can be imple-
mented immediately by the end users. Some of the recom-
mendations are considered to be “best practice” approaches,
which could potentially provide a more accurate measure of
CAD performance. However, such “best practice” approaches
may require significant effort and additional tools. The advan-
tages and disadvantages of these “best practical approaches”
are discussed in Secs. II.A–II.C and summarized in Sec. VI.
It should be noted that the testing procedures discussed in
Sec. II do not cover all the testing that may be required for
all possible CAD systems. For example, additional QA pro-
cedures may be required for CAD systems intended for de-
termining the likelihood of malignancy for a suspicious ab-
normality, and estimating the risk of developing a disease or
not responding to treatment. On the other hand, many medi-
cal imaging analytic software packages that are used to assist
in diagnosis and decision making may not necessarily be la-
beled “CAD” (for example, software to segment lesions or
superimpose a parametric color map on a displayed image).
These packages could potentially benefit from QA testing. Al-
though the specifics and extent of the testing may vary from
one application to another and we often use the more com-
monly used lesion detection CAD as examples, the general
principles and considerations discussed herein should be ap-
plicable to the various types of computer-assisted diagnostic
software tools.
II.A. General guidelines on QA for clinical
CAD systems
Seven questions were used to guide development and rec-
ommendation of a set of general guidelines for CAD QA pro-
cedures.
Q1. When does a QA procedure need to be performed?
Q2. Who should perform the test?
Q3. What are the tools and materials that may be used to
perform the QA tests?
Q4. What are the performance measures to be used?
Q5. What QA results should be captured and how should
they be reported?
Q6. What are the criteria of success/failure of the tests (or
minimal requirements)?
Q7. What should be done if the CAD QA test fails?
Responses to these questions were not made specific to a
particular CAD application and are detailed below.
Q1. When does a QA procedure need to be performed?
R1. CAD QA test is recommended for the following
situations:
a. Performance verification/conformance to specifications
(as stipulated by the manufacturers via the user man-
ual, promotional materials, scientific publications, etc.)
at the first installation or subsequent CAD software up-
grades, including operating system upgrades,
b. Replacement or upgrade of imaging system hardware
or software components that affect image quality (e.g.,
x-ray tube, energy source, detector, or image recon-
struction algorithm),
c. Check for interaction or impact on the CAD software
when other software or upgrades are installed on the
same workstation on which the CAD system resides,
d. Any experience of performance deviation from the
original specifications,
e. Specific procedures identified as necessary to be per-
formed on a regular basis (e.g., monthly, quarterly,
yearly) to assure performance consistency,
f. Change in image acquisition parameters, e.g., change
in mAs, kVp, image reconstruction algorithm.
Q2. Who should perform the test?
R2. CAD QA should be performed by designated quality
assurance personnel with adequate training to perform the QA
procedures, e.g., technologist, medical physicist, radiologist,
and manufacturer.
Q3. What are the tools and materials that may be used to
perform the QA tests?
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R3. CAD QA may use the following materials and tools:
a. Software tools provided and validated by CAD manu-
facturers or third party providers for:
– Saving and retrieving user-selected image data to
and from user-designated QA directories to ensure
that the QA directories are separated from the local
patient image storage or long-term patient archive of
the clinical site,
– Marking, validating, and storing appropriate refer-
ence standards (e.g., lesion location, pathology, and
boundary) for the CAD system of a given applica-
tion (e.g., detection, diagnosis, segmentation) in a
CAD manufacturer-specified format for automated
scoring of the CAD output (scoring refers to, e.g.,
the process of determining whether a CAD mark is
a true positive or false positive, or the accuracy of a
quantitative measure, by comparison with the truth
or reference standard based on some defined mea-
sures or rules),
– Storing CAD system output, such as CAD mark lo-
cations, lesion malignancy estimates, etc., if it is not
an option available to users already,
– Reading CAD system output, which may be stored
as Digital Imaging and Communication in Medicine
(DICOM) standard objects/files, for any user-
selected cases (such a reading tool is important for
many purposes, especially QA, and is not commonly
available like a DICOM image reader),
– Displaying CAD results for QA purposes,
– Calculating performance measures (see responses/
recommendations to Q4).
b. A set of clinical images (of appropriate version, e.g.,
“for processing” or “for presentation,” depending on
the required input of the CAD system) with appropriate
known reference standards provided by the CAD man-
ufacturer or collected at the clinical site for the CAD
system as described above.
c. Phantoms that are validated for a specific CAD QA pur-
pose with a validated test procedure.
Q4. What are the performance measures to be used?
R4. Performance measures depend on the application of
the CAD system and the purpose of the QA tests. For test-
ing CAD system performance, the measures may include, for
example:
a. CAD detection mark rate over time and stored in the
CAD system (display time-series graph at the user de-
mand for QA),
b. Sensitivity, i.e., the ratio of correctly marked lesions to
the total number of lesions evaluated, relative to the ref-
erence standard. In some applications, sensitivity needs
to be calculated for individual lesion types (e.g., mass,
microcalcifications) or within certain regions (e.g., lung
nodules behind the heart on chest radiographs, in the hi-
lar region versus lung periphery for lung CT),
c. Segmentation accuracy, using an appropriate measure
for the application (e.g., comparison of size or vol-
ume with the reference standard, an appropriate over-
lap measure or boundary comparison with the reference
standard),
d. Malignancy/benignity assessment accuracy [e.g., area
under the ROC curve or (sensitivity, specificity) pair].
The following should be noted:
(1) When assessing detection sensitivity, it is advisable to
report the characteristics of the cancers evaluated, for
example, in terms of the number of cases for different
cancer types, sizes of the lesions, and other character-
istics, which may affect the sensitivity.
(2) Other applications such as characterization and seg-
mentation may also be affected by lesion characteris-
tics (e.g., lesion size, spiculated lesions vs nonspicu-
lated lesions, etc.). Descriptors of the data sets should
be part of the stored reference standard.
(3) QA tests described here are mostly to track relative
performance changes within the same data set. End
users should be cautioned that the QA performance
results may not be compared directly to performances
estimated for the “patient population” reported by the
CAD manufacturers or by other studies, unless the
data set is representative of a similar population and
the sample size is sufficiently large. The user should
also be cautioned that sensitivity and specificity per-
formance will change with each version of software
as documented in the labeling for each version. CAD
output such as the locations of CAD marks or segmen-
tation boundaries may also change.
Q5. What QA results should be captured and how should
they be reported?
R5. The following data may be captured, tracked, and re-
ported from either visual assessment or automated computer
analysis:
a. Log files with:
– Date and reasons to perform the QA tests,
– Personnel who perform the tests,
– QA procedures or tasks performed,
– Locations where the test data and results are stored
if electronic storage is employed.
b. Performance measures (see responses to Q4)
c. Screen shots capturing CAD results on the image
d. Noticeable changes in performance over time or when
compared with product specifications
e. Failure in communication between CAD systems and
other necessary devices (e.g., acquisition system, dis-
play workstation, other imaging devices)
f. Record of intermediate results that are deemed to be
necessary or critical (e.g., segmentation of the organ,
feature values).
Q6. What are the criteria of success/failure of the tests (or
minimal requirements)?
R6. The tolerance limits or criteria of success/failure for
each specific QA test will depend on the application, sample
Medical Physics, Vol. 40, No. 7, July 2013
077001-5 Huo et al.: QA/training for CAD system use 077001-5
size of the test data set, and require further research and dis-
cussion. As general principles:
a. For periodic QA procedures, hardware or software
changes, or experience of performance deviations: def-
inition of the level of change in performance (if any) as
acceptable, passable, worrisome, or unacceptable,
b. For CAD system upgrades: tolerance limits if perfor-
mance decreases but no limit on improvement.
Q7. What should be done if the CAD QA test fails?
R7. If the CAD QA procedure fails, the following actions
should be considered:
a. Trouble-shooting of whether a change in hardware or
software, that may or may not be part of the CAD sys-
tem (e.g., a display workstation software upgrade or a
change in image detector), affects CAD performance,
b. If the failure is a result of a discrepancy between the
site’s own test data and other data, investigation of
whether the site’s own test data set is representative of
the larger patient population,
c. Investigation to assess impact of changes in perfor-
mance and alert site users of potential problems,
d. Contact device developer or manufacturer.
II.B. Assure functionality and performance of CAD
according to vendor’s specifications
II.B.1. Acceptance testing at installation
and subsequent upgrades of the CAD system
Currently, CAD QA procedures (or acceptance testing) are
performed by most CAD manufacturers at the initial instal-
lation and subsequent CAD software upgrades based on the
manufacturers’ own procedures and using the manufacturers’
test sets. These data sets are usually small. Acceptance testing
procedures ensure that the CAD or upgraded CAD is installed
properly, functions correctly, and integrates properly with
image acquisition and display hardware and software (e.g.,
DICOM compatibility). Such procedures should be adopted
by all CAD manufacturers including those that market and
deliver the CAD system through the Internet. The test results
should be documented as a reference for future QA of consis-
tency. There are also situations where the clinical sites want
to repeat such acceptance testing procedures using either the
manufacturer’s sample test set or their own independent data
set(s) (see requirements on data sets in Sec. II.B.3). It is there-
fore important that all clinical sites be trained and encouraged
to perform CAD acceptance testing. Such QA procedures can
be implemented immediately at clinical sites.
Currently, results of such acceptance testing or QA proce-
dures are not documented at clinical sites. It is recommended
that the test records should be kept (for example, in the form
of a log book or archived in a designated QA database) to
allow subsequent review and comparison. As recommended
in general guidelines R5 (see Sec. II.A), these may include
the CAD final output results as well as intermediate results,
pertinent notes on the results obtained, and any relevant in-
formation on problems encountered during the installation
or upgrades of the CAD system. QA personnel at the clin-
ical sites should independently evaluate performance in ac-
cordance with the specifications given by the CAD manufac-
turer. Adequate training and written instructions provided by
the manufacturer are necessary to ensure that site personnel
can perform QA tests correctly.
For an upgrade of the CAD software, the manufacturer
should inform the site personnel of any expected changes.
The site personnel should be advised to compare the CAD
results before and after the upgrade and communicate any un-
expected differences. It is important to understand whether or
not the differences are intended by the upgrade. However, if
the test set is small, one may not see the expected differences
(e.g., performance improvement) due to statistical uncertain-
ties. Longer-term tracking such as the CAD mark rate (de-
scribed below as a routine automatic QA procedure) and the
end users’ qualitative or quantitative reporting of any perfor-
mance change (e.g., radiologists’ observed sensitivity of the
CAD system) may be needed.
II.B.2. Installation of non-CAD software
on the same workstation
For some modalities such as mammography, only the soft-
ware for display of the CAD output is provided on the work-
station. However, if a clinical workstation is a part of the pic-
ture archiving and communication system (PACS), the work-
station may also offer software for display or analysis of
other image modalities. The different software may have un-
foreseen effects on one another, most likely resulting from
changes in the system configurations when software is in-
stalled or upgraded. Therefore, when other software (either
CAD or non-CAD) is installed on a workstation or PACS sys-
tem, it is important to perform QA procedures of all software
(including CAD) that resides on the workstation in order to
verify that it still functions correctly and in accordance with
performance specifications. The results of QA tests for CAD
should be identical before and after installation of other soft-
ware on the workstation. As such, comparison of previous and
current CAD marks, or quantitative outputs for some CAD
systems in a few test images, should suffice. Such QA pro-
cedures can be implemented immediately and encouraged at
clinical sites.
II.B.3. CAD QA test sets
A fixed set of test cases is recommended for acceptance
testing at the first installation and subsequent upgrades of the
CAD software. For convenient QA testing of consistency in
performance, use of a CAD manufacturer-provided data set is
appropriate. This data set should represent the typical perfor-
mance of the system, and the specific CAD behavior on those
cases, including truth, locations of CAD marks, and resulting
sensitivity and specificity (or other quantitative output) should
be well documented. Such test sets can be made available im-
mediately to the end users.
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Because a manufacturer’s sample is likely to be limited and
thus cannot be considered representative of the patient popu-
lation seen at individual clinical sites, clinical sites are also
encouraged to collect their own sets of test cases for perfor-
mance assessment. It is advisable to collect a sufficient num-
ber of cases and use the automatic analysis tools to obtain a
reliable estimate of the average performance. The data sets
may come from existing databases at that site or third party
sites, or they may be collected prospectively after installation
of the CAD system. For a user-collected independent test set,
the user is responsible for collecting reference standards re-
quired to assess the CAD system performance, following in-
structions and using tools provided by the CAD manufacturer
(e.g., a bounding box or an outline of the lesion for marking
lesion location stored in a specific data format and directo-
ries). The reference standard for each case has to be estab-
lished by a clinician or other qualified personnel.
It is recognized that collecting such independent test data
sets will require both additional effort and experience. The
motivation for this additional, independent testing is that it
will not only provide a higher level of QA to monitor CAD
system performance in the local patient population, but it may
also improve the effectiveness of end users’ use of CAD by in-
creasing their understanding of CAD performance in the local
population.
II.B.4. Manual vs automatic assessment of CAD QA
performance
The CADSC group members recognize the importance of
both visual and automatic evaluation of CAD performance.
Visual assessment of individual cases allows users to review
images along with CAD output. It provides users the opportu-
nity to assess performance specific to lesion type and identify
any quality issues related to the display of CAD results. For
lesion detection CAD systems, for example, users can track
the performance by counting and visually assessing the CAD
marks. However, it will be impractical, if not impossible, to
score manually the overall performance of the CAD system
in a substantially large data set or compare the results quanti-
tatively or statistically with some expected performance level.
Therefore, it is recommended that CAD system manufactur-
ers provide built-in automatic scoring functionality. This au-
tomatic QA will run the test cases in batch mode and report
the resulting sensitivity and specificity relative to the collected
reference standards. On the other hand, even with fully au-
tomatic QA, it is recommended that each clinical site per-
forms visual checks to ensure that the output of the CAD sys-
tem, such as lesion segmentation or CAD mark locations, is
reasonable and consistent. Automatic analysis would require
proper evaluation software tools and validation of the refer-
ence standards used for scoring (see details in Sec. II.A re-
sponses and recommendations to Q3). Periodic manual/visual
checks can be advocated and implemented immediately at
clinical sites. Automatic assessment of CAD QA performance
would be the best practice approach but may require signifi-
cant effort from CAD manufacturers or any pertinent parties
to implement or incorporate the functionality as QA tools.
It is recognized that even with fully automatic scoring and
reporting, the interpretation of test results for locally collected
data may be more complex than testing with the manufac-
turer’s data set. For example, the local CAD performance may
differ when compared against the manufacturer’s claims or
tests conducted at other sites. The difference may be attributed
to many factors, such as (a) a true difference in the CAD per-
formance if the test set is sufficiently large and representative
of the local population, (b) difference in the image quality be-
tween the local data set and the manufacturer’s data set, (c)
statistical uncertainty due to the sample size of the indepen-
dent test set, or (d) one or both of the test sets are biased.
As discussed elsewhere in this report, such variability may
or may not necessarily indicate problems with the CAD sys-
tem, and the interpretation of such test results in the absolute
sense requires caution. Some guidelines on independent test-
ing, sample size, and quality of the test data set, and statistical
interpretation of test results may be found in a report to be
published by the AAPM CADSC Groups 1 and 23 and in the
literature.4, 5
II.C. Assure consistency of CAD system performance
over time
Tracking the performance of a CAD system over time is
an important QA procedure to ensure that the CAD system is
consistent within its performance specifications. Tracking the
performance after initial installation could help monitor, for
example, whether variability that may occur in a component
of the imaging chain affects the performance of the CAD sys-
tem, or whether an upgrade by the CAD manufacturer actu-
ally improves the performance in the local patient population.
CAD systems for lesion detection are discussed below as an
example.
II.C.1. Tracking the number of CAD marks per image
over time
Tracking the number of CAD marks per image over time
on routine clinical cases is the most efficient and effective
way to detect any unusual behavior of a CAD detection sys-
tem. The QA procedure to track the running average number
of CAD marks per image over N consecutive patients at any
given time can be completely automated. The CAD mark rate
monitor (in the form of a graph giving the average number of
CAD marks as a function of time) may be inspected period-
ically by QA personnel. Visual inspection of the time-series
plot could greatly inform the end users on the stability of the
CAD system over time. An unexpected trend or sudden in-
crease/decrease in the CAD mark rate will be a cause of con-
cern and warrant investigation. If the QA test on an archived
data set does not show a change, but deleterious changes are
observed with routine clinical cases, the imaging chain should
be evaluated for changes in image acquisition and processing.
Such a QA procedure is reasonably easy and practical to im-
plement, but it requires development of an automated record-
ing and storage capability for the number of CAD marks for
each image as well as software to generate and display a graph
of the QA results.
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II.C.2. Checking sensitivity of CAD system
The sensitivity of a CAD system is another important CAD
QA index. As described in Secs. II.B.3 and II.B.4, it is impor-
tant to evaluate the CAD performance on a clinically repre-
sentative database. However, additional effort is required to
establish an independent database of abnormal cases and to
perform automatic performance evaluation. It should be noted
that once the database is established, the database can be used
to check the sensitivity of the CAD system both for new in-
stallation and after subsequent upgrades. An alternative to ac-
cumulating consecutive abnormal cases by the end users is to
use a third-party or public database, if available.
In addition, CAD manufacturers could provide software
tools that allow users to collect the data set and reference
truths and calculate the sensitivity as described in the general
guidelines (see Sec. II.A) to facilitate such evaluation in case
the end users want to evaluate the sensitivity of the CAD sys-
tem on their own patient population. Whether the sensitivity
assessment on a nonmanufacturer-provided data set should be
included as an acceptance or a routine QA test will be a topic
of discussion for the CAD community.
III. RATIONALE AND RECOMMENDED
PROCEDURES FOR TRAINING RADIOLOGISTS
AND TECHNOLOGISTS ON CAD USE
To attain the full benefit of CAD, CAD users should be
trained in the use of CAD. However, best practices have not
been established for CAD training. Radiologists have been
anecdotally somewhat resistant to formal CAD training. The
purpose of the training is to educate the physicians on the in-
tended use of the CAD system, although it is recognized that
much of the physician’s education occurs during clinical use.
For example, research shows that the learning curve for radi-
ologist use of CAD changes over the course of a year. In one
study, breast radiologists initially increased their recall rate
when using CAD, but over a year, the recall rate decreased to
near the level before CAD implementation.6
Understanding what a CAD system has been designed to
do and its limitations is important because using CAD beyond
its intended capability can lead to ineffective or even harmful
results, so user training is necessary. Training may be costly,
and changes in personnel often mean that more training is
necessary. Possible solutions include web-based training, but
there is no substitute for one-on-one training and case-based
training, which may be incorporated as a part of residency
training. In recent years, CAD has been added to RSNA train-
ing modules for mammography.
Some of the important questions relating to training of
CAD use that could be addressed through research include:
 How can we encourage radiologists to spend time get-
ting trained?
 Does the absence of training impair CAD performance
in the clinic?
 Is there an association between radiologist performance
and attitudes toward CAD before and after training?
III.A. Importance of understanding the effect of
improper use of CAD on sensitivity and specificity
The need of user training can be exemplified by CAD
systems for lesion detection. It is critical for end users to
understand the sensitivity and the average number of false
positives per image in order to work effectively with these
CAD systems. Each CAD system will have its own unique
strengths and weaknesses depending on how it is developed
and the data are used as a part of the development process.
For example, the characteristics of the true-positive and false-
positive detections may vary significantly from one system
to another, even for CAD systems that have a similar perfor-
mance in overall sensitivity and specificity. Proper training
with clinical examples may significantly reduce the difference
in learning curves among end users and potentially shorten the
learning time.
Understanding the specificity and the types of false-
positive detections is important for end users to use a CAD
system efficiently and effectively, especially when false-
positive detections are different from the typical false pos-
itives detected by clinicians. Proper training can help end
users learn to dismiss certain types of false-positive detec-
tions, avoiding unnecessary workup or even biopsy.
The use of CAD systems in unapproved reading modes
(e.g., off-label use) can adversely affect sensitivity and speci-
ficity and is discussed in Sec. IV.
III.B. Frequency and type of training
Training at initial installation is recommended. Whether
retraining will be needed when CAD is modified or improved
may depend on the magnitude of the change. It would be help-
ful to have recommendations as to whether additional train-
ing is necessary. From the perspective of the clinical site,
the question is whether the change is substantial. The ven-
dor should provide detailed documentation regarding what
has been changed and what the user may expect. The site
should perform CAD acceptance testing (see Sec. II.B.1) with
the same test set that was used for initial acceptance testing
to verify whether the observed change in performance agrees
with the vendor’s description. The radiologists can inspect the
CAD marks before and after the change on the onsite test set
to learn how the CAD marks change (see Sec. II.B.4). Seeing
the specific changes in the CAD marks on a number of test
cases will be the best training for radiologists.
The American College of Radiology (ACR) is actively en-
gaged in training radiologists. ACR has included CAD in their
Breast Imaging Residency Training Curriculum, which may
pave the way for CAD training in other applications when
they become more prevalent. Radiologists will likely accept
structured training and prefer the integration of CAD in ex-
isting clinical training courses, continuing medical education
(CME) and accreditation, rather than being offered as a sep-
arate course. Variations in the performance of CAD systems
should be considered in the design of training courses. Mam-
mography Quality Standards Act (MQSA) or other regulatory
processes may impose training requirements for mammogra-
phy and other CAD, respectively.
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Technologist training may be useful, especially if radia-
tion dose or patient positioning affect CAD, which may be
especially important for less mature CAD applications. CAD
should be assessed per modality and application to determine
whether technologist training is essential, an assessment that
could be made by the American Society of Radiologic Tech-
nologists (ASRT).
There are no guidelines or research on the conduct of
CAD training or how much training is needed. A few stud-
ies observed that training affected radiologists’ performance
with CAD.6, 7 However, more research is needed to investi-
gate how much training is required and how much variation
there is among radiologists of different clinical experiences
or practicing in different settings. It is also unknown whether
CME would be helpful and, if so, to what extent. This situa-
tion presents an opportunity for collaboration among AAPM,
ACR, and RSNA to encourage training on CAD use, deter-
mine how much training is necessary, and organize appropri-
ate refresher courses for the various purposes.
III.C. Training the vendors: Feedback on CAD
performance
Clinician or end user feedback to the vendor is an inter-
esting topic. In a sense this is mutual training, not only for
the clinician but also for the vendor. For example, the radi-
ologist could send the CAD vendor examples of frequently
missed cases that could point out a weakness in the system.
The CAD vendor will usually first ask whether the missed le-
sions are mostly malignant. If benign, and such lesions are not
part of the intended use of the system, then this is an opportu-
nity for the vendor to educate the radiologist that the system
is not meant to detect benign findings. Continuous feedback
from the users to the vendors (and vice versa) is crucial and
should be encouraged since it can accelerate improvements in
the CAD systems. This is an example where auditing (moni-
toring the CAD performance) at the users’ sites will be useful
for the vendors. If the users accumulate statistics on how the
CAD system performs and record cases that are missed by
CAD, the vendors may get feedback from these results. Such
a process is probably partially being done already at some
institutions as a part of an educational process, internal audit-
ing, or research, so it may not cause a lot of additional work.
However, the vendors have to provide functions to facilitate
such a process, for example, recording callbacks that have no
CAD marks, CAD marks that cause additional callbacks, re-
calling CAD marks on prior exams when a current exam is
being read, etc. The last function will help radiologists iden-
tify if a newly diagnosed cancer was marked in the prior exam
but ignored. This kind of feedback will be valuable as a con-
tinuing training process for the radiologists to learn how to
trust or discard CAD marks.
III.D. Storing CAD marks long term
for training/auditing purposes
It was suggested that AAPM recommend long-term stor-
age of CAD results. In the not-too-distant future, when the
electronic health record (EHR) is more widely implemented,
there will be massive databases of images, results, and long-
term follow-up. CAD output should be a part of the long-term
electronic record to allow healthcare professionals, vendors,
and researchers to perform a variety of interesting analyses.
Radiologists have not wanted to store CAD results because of
a concern over medicolegal issues, but this concern has mostly
not been borne out in the courts.8
The storage of CAD marks has many potential advantages.
It will facilitate automatic monitoring of the stability of the
CAD system performance over time (see Sec. II.C.1). It may
help the radiologists to learn the characteristics of dismissed
CAD marks on prior exams that turn out to be true lesions
in current exams. It is also possible that the CAD system can
use previous readings to improve its current performance af-
ter being trained to do so.9 Analysis of the CAD prospective
performance in large populations will allow further research
and development to improve the CAD systems. On the other
hand, the current lack of audit trail of CAD may diminish
CAD’s role as a serious diagnostic tool, and even question its
reliability and scientific vigor. The lack of records also makes
it difficult to conduct large clinical trials with proper study
designs to evaluate the impact of CAD in routine clinical
practice.
Most mammography CAD actually analyze a “for process-
ing,” or raw image, that is not stored unless the clinical site
chooses to store it. The radiologist reads a processed image
known as “for presentation.” The same may be true for digital
chest examinations and lung CAD. Thus, once the raw image
is deleted, it may not be possible to recreate prior CAD marks
from scratch. The same paradigm may apply to CT colonog-
raphy. For example, there may be a role for CT colonography
CAD to use thinner slices than those used “for presentation.”
In such situations, it will be even more important to store the
CAD marks as a part of the electronic record. The same con-
siderations should be given to other CAD systems that provide
quantitative image analysis results or decision support to clin-
icians, similar to what is being done for many other non-CAD
diagnostic tools.
IV. OFF-LABEL USE
Off-label use of CAD is using CAD in a manner that is
not specifically stated in the FDA-approved indications for the
CAD system. Physicians may use any FDA-approved product
off-label according to their professional judgment concerning
the needs of their patients. However, there is a concern that
CAD will be used off-label in ways mainly to improve physi-
cian productivity such that the diagnostic performance of the
physician plus CAD could fall appreciably. The issue here is
how to handle off-label use of CAD.
Off-label use is more of a problem for radiologists when
CAD is less sensitive than the human reader. For example,
if the CAD system is labeled to be used only in the second
reader mode, using it in the first or concurrent reader mode
could potentially result in a degradation in sensitivity. This
would be of particular concern when the CAD marks on the
image are a mixture of output from two systems, one with
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presumably higher sensitivity (e.g., microcalcification detec-
tion) and the other with lower sensitivity (e.g., mass detec-
tion) than the radiologists, as in mammography. This higher
sensitivity of CAD microcalcification detection might mis-
lead radiologists to be less vigilant with their own reading
and inappropriately use CAD in the first or concurrent reader
mode. While the off-label use of the CAD marks might not
cause much harm for the detection of ductal carcinoma in situ
(mainly microcalcifications), the sensitivity for detection of
invasive cancer (mainly masses) might suffer.10 The concur-
rent reader paradigm might lead to satisfaction-of-search er-
ror. For example, while focusing on the primary disease-of-
interest such as a lung nodule or colonic polyp marked by the
CAD system, radiologists might be distracted from searching
for lesions that the CAD system misses and might overlook
secondary findings on other parts of the image.
As a general principle, the CADSC group notes that off-
label use of CAD is not a good practice. This recommendation
should be stated unequivocally because the impact of CAD
depends strongly on reading paradigm.
IV.A. Means and practicality of controlling the reading
environment
Presently, the reading environment including the off-label
use of CAD is not monitored or recorded. There are concerns
that readers may convert second-read-approved CAD to con-
current read and concurrent-read-approved CAD to first read.
It is difficult to know how to discourage such behavior. Train-
ing is one way to do so. Another is to record or track reading
behavior. The readers will know that they are being moni-
tored and will be less likely to cut corners and use CAD off-
label. The recording could consist of storing reading times
and clicks as an audit trail.
Another more intensive approach is to record the CAD
reader behavior while interpreting the images without and
with the use of CAD in more detail. For example, the radiolo-
gist’s findings could be recorded prior to displaying the CAD
output. That way the pre-CAD readings would be available
for auditing. The CAD vendors could control the workflow by
modifying the display protocols. However, there is a concern
that such auditing by the workstations might not be practical
because in some review workstations CAD does not control
the reading environment. The display protocols and the abil-
ity to audit CAD usage are functions of the workstations, not
the CAD systems. In such situations, collaboration between
the CAD vendors and the workstation vendors, if they are not
the same, will be crucial for implementing CAD in the work-
station with the proper control of CAD output display. Some
thought should be given to adding these requirements to In-
tegrated Healthcare Enterprise (IHE) protocols. Another pos-
sibility is to record the CAD metadata either in the DICOM
header or in an alternative structure such as Annotation Imag-
ing Markup (AIM), part of the National Cancer Institute’s
caBIG R© (cancer Biomedical Informatics Grid R©) initiative.11
The situation is further complicated because the physician
may use multiple software tools when interpreting a case. For
example, the radiologist often prepares final study reports us-
ing a dictation system; there may be no physical connection
between the CAD and the dictation software, which raises
the question as to whether the reporting functions of specialty
CAD workstations are wasted.
Another issue is who would perform the audit. Manufac-
turers have no authority to perform audits. If the FDA or an-
other entity were given the authority (similar to MQSA), they
could audit reader performance with CAD. To have a more
practical solution to off-label use, more feedback from physi-
cians about how to accomplish this goal in a positive, sup-
portive manner will be needed. How to design workflow to
prevent off-label use of CAD is a good research topic.
IV.B. Standardization
Standardization can be helpful for advancing the clinical
implementation of new imaging technologies and third party
QA software tools, and reduce user training efforts for both
QA personnel and clinical users. Examples of standardiza-
tions for CAD include technical and clinical functions such
as file formats, reported data elements, and application pro-
gramming interfaces (APIs) for PACS integration of CAD.
Standardization, however, can be undesirable for the vendor
community because it can become more difficult to differen-
tiate one’s product from that of others. A possible solution is
to minimize the subset of functions on the workstation that
requires standardization. Standardization is a driver to con-
formity and hence must be made attractive to the vendor. To
identify the minimal requirements for CAD standardization,
a community of users and vendors should form a forum in
which all interested parties in the CAD community (manufac-
turers, healthcare professionals, academic researchers, gov-
ernment entities, public advocate organizations, and regula-
tors) can communicate efficiently. It is suggested that the
Medical Imaging and Technology Alliance (MITA) organizes
and participates in such a forum.
Standardization requires extensive discussions to achieve
acceptance or “buy-in.” A successful example in this area is
the development of mammography display and printing qual-
ity control standards. The FDA asked the vendor community
for consistent quality control recommendations, so the ven-
dors prepared such recommendations through MITA. There
are also practical limitations to incorporating requirements,
and an underlying set of standards would help. For example,
the IHE (http://www.ihe.net/) helps narrow the DICOM stan-
dard to make it more feasible for vendors to implement. The
discussion forum of the CAD community can work together
to identify relevant standards.
Some of the recommendations regarding standardization
for CAD are as follows: (a) CAD output should be stored for
quality assessment and research. The CAD output should be
stored as metadata either within the DICOM image header or
using another standardized system such as caBIG’s AIM data
structure. (b) CAD should be made a part of hanging protocols
in accordance with indications for use of the CAD to enable
internal auditing if necessary. (c) Standardization of certain
aspects of CAD implementation and usage may be helpful.
Survey and discussion should be conducted to determine what
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standards exist that might be relevant for CAD and what other
standards may be needed. The goal is to rely on existing stan-
dards to integrate QA into CAD and limit the number of new
standards that would need to be developed.
V. FUTURE CAD QA PROCEDURES: POTENTIAL
APPLICATIONS AND RESEARCH OPPORTUNITIES
There are opportunities for QA research all along the CAD
development and utilization pipeline. Research with phan-
toms and simulated images may reduce the burden of human
data collection for certain QA procedures and CAD develop-
ment. As CAD moves from development to deployment, there
are research opportunities for QA in the healthcare setting and
in the evaluation of training and performance of clinicians us-
ing CAD. After CAD has been established in a medical prac-
tice, utilization of large electronic health records will facilitate
monitoring CAD performance changes over time and evalu-
ating effectiveness of CAD.
A majority of the topics covered in Secs. II–IV require fur-
ther research, for instance, to refine the design and mecha-
nism of the recommended procedures for implementation of
CAD QA and training, to define specific or alternative pro-
cedures, to expand QA to all types of CAD applications, to
develop standardized QA procedures and tolerance limits for
each type of CAD system, and to understand and evaluate the
cost and efficacy (e.g., impact on workflow and clinical out-
comes) of QA procedures. Such research efforts will certainly
require collaboration from all parties involved in CAD (i.e.,
device manufacturers, clinicians, academic researchers, gov-
ernment entities) as well as funding.
This section covers other potential research opportunities,
for example, alternative procedures using phantom and simu-
lated images for CAD QA, the assessment of radiologist per-
formance and training methods, and the use of national EHR.
V.A. Phantoms and simulated images for CAD QA
Physical phantoms, partially digital phantoms (e.g., simu-
lated lesions digitally superimposed on real patient images),
or totally digital phantoms (e.g., digitally simulated images
and lesions) are increasingly used for device design and devel-
opment and for understanding limitations of certain devices
or procedures. It may be envisioned that such phantoms could
also be employed for certain types of CAD QA procedures
instead of collecting a large set of real patient images with
reference truth. For example, phantom images may be useful
for monitoring CAD software consistency or reproducibility
over time. Of course, the practicality of a phantom approach
depends on many factors. One important question is whether
the CAD system response to the phantom images is close, at
least in a relative sense, to its response to real patient data.
The use of phantoms will most likely lower the burden or cost
to the end users and/or CAD manufacturers, which makes it
an attractive alternative for consideration. To date, very lim-
ited research has been performed on the use of physical or
partially/totally digital phantom image databases for QA pro-
cedures of CAD products. This may be explained by the very
limited number of available phantoms and, to our knowledge,
none have been developed and accepted for the purpose of
testing CAD systems.
Physical or partially/totally digital phantom image
databases are worthy of consideration as potential resources
for CAD QA procedures. Once a simulated lesion database
is developed, it can be reused at different sites and can sub-
stantially reduce the effort for clinical image collection. Phys-
ical phantoms can capture the effect of variations in the imag-
ing chain on CAD performance, but the limitation of physical
phantoms is that it is cost-inhibitive to build a large set of dif-
ferent physical phantoms that will realistically cover the vari-
ations in the anatomical structures and lesion characteristics
in the patient population. If the purpose of using the phantom
images is limited to certain QA procedures that monitor rel-
ative changes, the requirements on the sample size and their
similarity to real patient characteristics may be less stringent.
The CADSC group recognizes that the design and valida-
tion of physical or digital phantoms will require long-term re-
search and development efforts that include consideration of
many issues such as:
 Designing phantoms of a specific anatomical region by
incorporating statistical variations in phantom structures
representative of patient population for a given CAD ap-
plication,
 Designing lesion features representative of patient pop-
ulation for a given CAD application,
 Defining relevant QA tests and the sample size needed
for the tests,
 Developing QA procedure protocols,
 Validating QA test protocols using phantom(s),
 Implementing a QA mode on CAD systems by manu-
facturers,
 Defining pass/fail criteria for QA tests using phantoms.
The purpose of the discussion is to stimulate interest in
the research and development of advanced phantoms or le-
sion models for specific CAD applications and the validation
of phantom use in certain associated QA procedure protocols.
If the phantom approach is developed and accepted by the
CAD community, it may facilitate implementation of QA pro-
cedures.
V.B. Assessment of radiologist performance
and training methods
The rationale and procedures for training radiologists were
discussed in Sec. III. This section describes two complemen-
tary training processes.
First, at the introduction of a new CAD system in each
clinic, the radiologists may be presented with a sufficiently
large set of cases with known lesions that capture a range of
difficulty without CAD and with CAD. Study of the CAD out-
put on real images may familiarize the radiologist with the
process and provide certain understanding of the CAD out-
put. Questions associated with this training process include:
(a) how many cases would be necessary so that the training is
effective, (b) should the cases be provided by the CAD vendor
Medical Physics, Vol. 40, No. 7, July 2013
077001-11 Huo et al.: QA/training for CAD system use 077001-11
or selected from the patient population as seen in the users’
respective practices? The former may be efficient, while the
latter may have the advantage that the CAD marks will re-
flect the specific image quality and characteristics in the lo-
cal clinic. Another question is whether retraining is needed at
each upgrade of the CAD system.
Second, during clinical use of a CAD detection system, for
example, the radiologists should periodically review workups
and biopsies that result from CAD marks and may display
CAD marks on prior exams in their routine reading. The re-
view may help reduce future overcalls due to false-positive
CAD marks and reinforce their confidence in true-positive
CAD marks. The display of previous CAD marks on the prior
exams may help the radiologists learn the properties of early
subtle lesions that may have been marked by the CAD sys-
tem and thus reduce incorrect dismissal of true-positive marks
in the future. In addition, archiving the CAD mark locations
of every examination, rather than deleting them as in current
practice, could better document the reasons than a dictated
note for recalling a patient and defining a specific focal lesion
for the additional workup. Research on the potential benefits
of these procedures would help guide clinical practice.
To determine the proper mechanism for training the radi-
ologists on the use of CAD, research investigations will be
needed to address the questions above. It will also be inter-
esting to determine the time period or number of cases that
is necessary for a radiologist (having received training or not)
to become consistent and most effective (i.e., optimal perfor-
mance) with CAD. It is noted that the feedback of results of
CAD in clinical use will require long-term storage and easy
recall of CAD marks, as discussed in Secs. II–IV.
Training of radiologists and technologists may also be re-
quired to optimize the preparation of patients prior to be-
ing imaged by systems that utilize CAD. For example, in
CT colonography, patients need to have an appropriate bowel
preparation and at the time of scanning need to have adequate
colonic distension and image resolution. Patient preparation
and acquisition-specific issues that bear upon the performance
of CAD should also be investigated.
In addition to training, other methods that may improve ra-
diologists’ proper use of CAD marks should be considered.
For example, radiologists’ interpretation may be improved
with the assistance of content-based image retrieval or with
probability estimates attached to the CAD marks. Although
some work has been published in these areas,12 much more
research will be needed to explore the different approaches
that may improve the effectiveness of radiologists using CAD
systems.
V.C. Monitoring CAD performance changes over time
and effectiveness using large electronic health
records
It is envisioned that the use of EHR could be a means for
government entities (e.g., MQSA for mammography), hospi-
tals, and physician practices to monitor CAD performance
(e.g., average number of marks per image) and its effect
on radiologist performance (e.g., average number of CAD
marks selected by the radiologist as abnormalities requiring
additional workup). Electronic connection with other clinical
information such as patient outcomes and long-term follow-
up data across hospitals may facilitate assessment of the im-
pact of CAD on healthcare. Recording the version of the CAD
system as well as the imaging system model and image ac-
quisition parameters would allow relevant stratified analyses
(e.g., per type of scanner used, per geographic region, ac-
cording to radiation exposure or patient preparation). Use of
EHR may provide useful and precise information on the im-
pact of CAD on the overall and subgroup performances and
thus help guide further improvement of QA procedures and
CAD use, as well as CAD research and development. FDA
currently does not monitor CAD systems, and there are eco-
nomic and medicolegal concerns considered as barriers that
prevent recordkeeping of CAD in clinical practice. Involve-
ment of governmental, professional, and patient groups could
be a significant part of introducing QA to CAD.
V.D. Funding opportunities
Funding is a critical component for moving forward re-
search and development efforts on QA of CAD. It would
likely be challenging to obtain grants for such efforts because
the topic may be perceived as lacking scientific innovation.
However, the key is to emphasize the practical clinical signif-
icance for establishing QA of CAD. It is increasingly recog-
nized that significant health benefits can accrue from quality
improvement.13, 14 Some of the funding agencies focus more
on basic research than on clinical implementation. Identifica-
tion of alternative funding sources such as those emphasizing
healthcare improvement and initiatives would be beneficial.
Proof of the benefits of auditing is potentially a fruitful re-
search focus.
VI. DISCUSSION AND SUMMARY
This paper discusses the rationale and recommendations
for QA procedures and training clinicians and clinical site
personnel regarding CAD systems used in clinical practice.
The QA procedures encompass principles for QA testing at
installation or upgrade of CAD and procedures to track the
consistency of CAD performance over time. Some of the
procedures are considered as practical and can be imple-
mented immediately and some are considered as “best prac-
tice.” These “best practice” approaches may require studies
to assess their effectiveness before implementation. For ex-
ample, the paper outlines the important roles of both man-
ual (visual review) and automatic analysis of CAD output
in QA processes. The visual review approach can be imple-
mented immediately. However, the automated approach can-
not be implemented immediately because it requires software
tools, as discussed in Sec. II.A. In addition, the automatic
analysis is recommended to be performed on a sufficiently
large data set in order to obtain meaningful outcomes. This
may require clinical sites to collect a large number of cancer
or disease cases for estimating CAD sensitivity. Although the
analysis can be performed automatically using the software
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provided by the manufacturers or a third party, the case col-
lection process is rather manual and labor intense. For sites
with a smaller patient volume and limited resources, it will
take a relatively long time to accumulate enough cancer cases.
The CADSC group recognizes that this process may not be
practical for routine QA in all clinical sites. However, it is
worthwhile to conduct further research to better understand
its cost-benefit tradeoffs as a “best practice” approach, as well
as to search for less burdensome methods that can facilitate
the case collection, for example, studying the minimum cri-
teria for establishing reference standards and the minimum
number of cases required for the specific QA purpose. In ad-
dition, the CAD community may collaborate to establish a
common data depository that includes geographic and demo-
graphic information to allow users to select a case mix to sim-
ulate the local patient population, thereby reducing the burden
on individual sites. Case sets collected by a third party that
meet quality requirements may also be evaluated as an op-
tion. It is expected that AAPM will form task groups in the
future to provide specific guidelines on assessment of CAD
systems, such as the criteria for reference standard, recom-
mended number of cases, etc., to end users who are inexperi-
enced in this area if this “best practice” approach is recom-
mended for certain CAD QA purposes or for clinical sites
that prefer to assess CAD performance in their local popu-
lation. Independent of QA applications, such a database will
be valuable for the purpose of user training. Adequate user
training on CAD could substantially reduce the time to learn
how to effectively work with CAD and potentially reduce the
variation among the users in their performance over time.
The “best practice” approaches could potentially provide
more accurate measure of the CAD performance at the local
site and better training of the end users on CAD use. How-
ever, they cannot be implemented without additional effort or
research. The potential impact on end-user clinical workflow
efficiency should be considered when determining require-
ments and the level of training that is necessary for proper
clinical use of CAD. Potential cost burdens on manufacturers
have to be considered to garner vendor support for these ac-
tivities and the final recommended QA procedures. It is envi-
sioned that CAD manufacturers may play a major role in CAD
QA by providing standardized software QA tools, which al-
low end users to perform QA tasks more efficiently and ef-
fectively. It may also be possible that a third party provider
can provide the standardized tools more cost-effectively by
reducing duplicate effort by individual CAD manufacturers.
Either way, it is recognized that CAD manufacturers’ partici-
pation is critical to the establishment of QA procedures and
implementation of QA tools. It would be productive if the
manufacturers share their experiences in QA, perhaps having
MITA (http://www.nema.org/prod/med/) and the CADSC as
a forum, and work jointly to design a common set of useful
and practical QA procedures at installation and for periodic
maintenance so that QA procedures will be performed in a
consistent manner across products from different manufactur-
ers. The goal is to bring CAD to an appropriate standard of
quality and facilitate acceptance testing and monitoring the
performance of CAD products at clinical sites.
QA of CAD systems for mammography may serve as a
starting point. Study of the cost and benefit impact of a QA
program for mammography CAD on patient care may pro-
vide a practical model to guide the design of QA programs
for CAD in general. Participation of the MQSA should be pro-
posed. Government entities’ engagement in this effort, as well
as development and implementation of regulations to include
inspection of the QA program of CAD systems, could be an
effective means to initiate QA monitoring of the proper use of
CAD.
The CADSC recognizes that reimbursement drives much
of the clinical use of CAD. While quality is important, in
practice it may take a back seat to cost and reimbursement
issues. However, we also believe that proactively seeking the
highest level of quality in CAD and documenting its benefits
in healthcare might convince payers to expand reimbursement
for CAD. Quality measures could impact reimbursement for
CAD, just as use of EHR and electronic prescribing affect re-
imbursement. It is expected that better QA could benefit the
patients and the end users, and ultimately lead to wider adop-
tion and reimbursement of CAD in clinical practice. These
are important factors that will sustain and drive research and
development in the CAD field.
Due to the diversity of CAD systems, the QA procedures
discussed herein do not encompass all possible tests that could
be important and necessary to perform on a CAD system.
For example, a CAD system that provides not only prompt-
ing capabilities to some suspected lesions but also the outline
of the findings that the system segments and determines as
suspicious could be subjected to an additional layer of QA
(i.e., those that will convey QA assessment of the segmenta-
tion accuracy). A CAD system that assists in estimating the
likelihood of malignancy of a lesion, predicting the risk of a
disease, or predicting the risk of recurrence or treatment re-
sponse will require different validation and QA procedures.
The recommendations are not intended to describe the spe-
cific procedures to be followed by the CAD end user or other
designated QA personnel, but rather to provide guidelines or
general approaches on how certain QA could take place and
be performed effectively. It is certain that these guidelines will
evolve through further discussions within the CAD commu-
nity before a QA program can be implemented and through
practical experiences after it is started clinically. Specific QA
procedures for a given CAD application will have to be de-
signed based on the application and the approved mode of
use. Collaboration among the clinical and CAD community
(i.e., academic researchers, healthcare professionals, software
developers, manufacturers, and government entities) is essen-
tial for the initiation of CAD QA procedures and for their de-
velopment, refinement, validation, and implementation in the
clinical arena.
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